Abstract
Objectives: The purpose of this study was to propose an integrated strategy for investigating the mechanism of Qiliqiangxin capsule (QLQX) to treat chronic heart failure (CHF).
Methods: Pharmacokinetics analysis was performed to screen the active components of QLQX using high-performance liquid chromatographyātandem mass spectrometry techniques. We then constructed the componentātarget network between the targets of active components in QLQX and CHF using Cytoscape. A network analysis, including topological parameters, clustering, and pathway enrichment, was established to identify the hub targets and pathways. Finally, some of the predicted hub targets were validated experimentally in human cardiac microvascular endothelial cell (HCMEC).
Results: We identified 29 active components in QLQX, and 120 consensus potential targets were determined by the pharmacokinetics analysis and network pharmacology approach. Further network analysis indicated that 6 target genes, namely, VEGFA, CYP1A1, CYP2B6, ATP1A1, STAT3, and STAT4, and 10 predicted functional genes, namely, KDR, FLT1, NRP2, JAK2, EGFR, IL-6, AHR, ATP1B1, JAK1, and HIF1A, may be the primary targets regulated by QLQX for the treatment of CHF. Among these targets, VEGFA, IL-6, p-STAT3, and p-JAK2 were selected for validation in the HCMEC. The results indicated that QLQX may inhibit inflammatory processes and promote angiogenesis in CHF via the JAK/STAT signaling pathway.
Conclusions: This study provides a strategy for understanding the mechanism of QLQX against CHF by combining pharmacokinetics study, network pharmacology, and experimental validation.
Introduction
Traditional Chinese medicine, characterized by a holistic approach, has attracted increasing attention worldwide because of its satisfactory clinical efficacy (; Zhang et al., 2015; ). Chinese herbal medicine, as the mainstay and principal form of traditional Chinese medicine practice, is composed of multiple herbal ingredients and hundreds of chemical compounds (Zhou et al., 2019). Hence, it is difficult to fully understand their effective ingredients and the mechanism of action which depends on the overall interactions among all the ingredients.
Qiliqiangxin capsule (QLQX), comprising 11 crude herbs, has been clinically used for treating chronic heart failure (CHF) in China, providing an effective alternative for treatments of CHF (; Tang and Huang, 2013; ). Chemically, flavonoids, saponins, cardiac glycosides, diterpene quinones, phenolic acids, diterpene alkaloids, and triterpenoids have been identified as the main constituents of QLQX (Yun et al., 2018). Recent pharmacological studies showed that QLQX performs various activities, including attenuating atrial structural remodeling (Tingting et al., 2019), improving endothelial cell function (), and protecting cardiac myocytes and mitochondrial function (Zhang et al., 2013). However, the active compounds, potential targets, and pathways involved in these effects have not been systematically investigated.
Recently, integrated strategies based on bioinformatics, system biology, and high-throughput analytical techniques have emerged as a holistic and efficient tool to solve this issue (; Xing et al., 2018; ). Network pharmacology gives us helpful tools to screen potential bioactive ingredients and understand the molecular mechanisms underlying the therapeutic effects by constructing componentātarget and targetādisease networks (; Yuan et al., 2017). In recent years, the network pharmacology-based method has been used to analyze the system-level mechanisms of mono- and poly-pharmacology, manifesting āmulticompound, multitargetā characteristics (; ). However, there exist limitations in the insufficient accumulation and poor quality of traditional Chinese medicine-related data, and the nonreproducible nature of the existing data (Zhang R. et al., 2019). The information on the active constituents of Chinese herbal medicine is critical for accurate assessments of the network. Thus, the greater the reliability and correlation of the information on the active constituents, the more convincing will be the results of network research. It has also been accepted that the components absorbed into the blood that attain a certain blood concentration can produce pharmacodynamics effects and are considered pharmacologically active substances (; ). Therefore, pharmacokinetics study provides powerful evidence for determining the main active compounds absorbed into the blood and deciphering their process in vivo.
In the current study, a comprehensive method focusing on the main active compounds was used to illustrate the molecular mechanisms of QLQX by adopting pharmacokinetics study, network pharmacological analysis, and experimental validation. The flowchart is illustrated in Figure 1. Briefly, (1) a pharmacokinetics study was employed to determine the main active components of QLQX; (2) a componentātarget (CāT) network was established to visualize the synergistic interactions between the targets of the main active components and CHF; (3) topological parameters of the CāT network, clustering, and pathway enrichment analysis of major hubs of QLQX against CHF were used to pinpoint the hub targets and pathways; (4) the hub targets determined by topological parameters and clustering analysis were used to construct the proteināprotein interaction (PPI) network; (5) some hub targets in the PPI network were experimentally validated in the human cardiac microvascular endothelial cell (HCMEC).
Figure 1
Materials and Methods
Reagents and Materials
The powder of QLQX was provided by Yiling Pharmaceutical Co. Ltd. (Shijiazhuang, China). Astragaloside, calycosin-7-glucoside, sinapine bisulfate, ginsenoside Rb1, Rb2, Rg1, Rg3, Rd, Re, Rf, and F2, salvianolic acid A, salvianolic acid B, danshensu, rosmarinic acid, protocatechuic acid, hydroxysafflor yellow A, formononetin, hesperidin, rutin, quercetin, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, and benzoylhypaconine were obtained from the National Institutes for Food and Drug Control (Beijing, China), and ginsenoside Rc, lithospermic acid, and aconitine were obtained from Shanghai Yuanye Biotechnology Co. Ltd. (Shanghai, China). High-performance liquid chromatography (HPLC)-grade methanol, acetonitrile, and ammonium acetate were obtained from Fisher Scientific International Inc. (Fair Lawn, NJ), and formic acid was obtained from CNW Technologies GmbH (Duesseldorf, Germany). HCMEC and complete growth medium [containing 90% high Dulbeccoās modified Eagle medium (H-DMEM), 10% fetal bovine serum (FBS), and penicillin/streptomycin] were purchased from BeNa Culture Collection (Beijing, China). Methylthiazolyldiphenyl-tetrazolium bromide (MTT) and bicinchoninic acid assay (BCA) protein assay kit were obtained from Beyotime (Shanghai, China). Rabbit antihuman monoclonal antibodies (JAK2, phosphorylated-JAK2, STAT3, phosphorylated-STAT3, VEGFA, and β-actin) and mouse antihuman monoclonal antibodies (IL-6) were provided by Beyotime (Shanghai, China). Rabbit antihuman monoclonal antibodies (ADRB1, ADRB2) were provided by Guidechem (Hangzhou, China).
HPLC-MS/MS Method for Pharmacokinetics Study
High-performance liquid chromatographyātandem mass spectrometry (HPLC-MS/MS) analysis (Shimadzu Co., Japan) was performed to assess the pharmacokinetic properties of 29 components in QLQX according to the method described in our previous study (Zhang et al., 2018). Briefly, chromatographic separation was achieved on an Agilent ZOBRAX XDB-C18 column (4.6 mm Ć 50 mm, 3.5 µm) maintained at 40°C. The mobile phase consisted of water (A) and methanol (B) both containing 0.1% (v/v) formic acid for astragaloside, calycosin-7-glucoside, sinapine bisulfate, and ginsenoside Rb1, Rb2, Rg1, Rg3, Rc, Rd, Re, Rf, and F2 detection with a gradient elution. The mobile phase consisted of water (A) and acetonitrile (B) both containing 0.1% (v/v) formic acid for salvianolic acid A, salvianolic acid B, danshensu, lithospermic acid, rosmarinic acid, protocatechuic acid, hydroxysafflor yellow A, formononetin, hesperidin, rutin, and quercetin detection with a gradient elution. The mobile phase consisted of water containing 5 mM ammonium acetate (A) and methanol containing 0.1% formic acid (B) for aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, and benzoylhypaconine detection with a gradient elution. The flowrate was set at 0.45 ml/min, and the injection volume was 10 µl. The quantitative analysis was performed with multiple reaction monitoring in positive and negative ion modes.
Plasma Sample Preparation
The powder of QLQX was diluted with 0.5% sodium carboxymethyl cellulose yielding a concentration of 0.13 g/ml suspension. SpragueāDawley rats were intragastrically administered with QLQX suspension at 1.3 g/kg, and the blood samples were collected into a heparinized centrifuge tube at 5, 10, 20, 40, 60, 90, 120, 180, 240, 360, 480, 720, and 1,440 min after dosing via the postorbital venous plexus. Then, the whole blood was centrifuged at 12,000 rpm for 10 min, the supernatant was obtained, and stored at ā80°C until analysis. The preparation of blood samples was conducted according to our previous research (Zhang et al., 2018). This study was carried out in accordance with the principles of the Basel Declaration and recommendations of guidelines of the National Institutes of Health. The protocol was approved by the Ethics Committee of Tianjin University of Traditional Chinese Medicine (Tianjin, China).
Targets Fishing
The targets of active components in QLQX determined by pharmacokinetics analysis were obtained from three databases: DrugBank,1 Swiss Target Prediction,2 and Similarity Ensemble Approach (SEA).3 Known therapeutic targets of CHF were collected from the DrugBank database1 and DisGeNet database4.The keywords āchronic heart failureā and ācongestive heart failureā were used, and the targets were human genes/proteins enrolled in this study.
Network Construction and Topological Analysis
The CāT network was constructed using Cytoscape (Version 3.2.1) (). Four topological features (degree, betweenness centrality, average shortest path length, and closeness centrality) were analyzed using Network Analyzer (). The major hub network comprising putative major components and major targets was extracted by defining nodes with degrees higher than the average number of neighbors.
Clustering Analysis
MCODE (Version 1.4.2) () was employed to identify the major hubs of QLQX against CHF. MCODE analyzes the network based on the given parameter, and it assigns the weight to the vertex in local neighborhoods from the dense regions using vertex weighting, cluster prediction, and optimal postprocessing. Finally, we defined the hub targets by considering the results of the topological analysis and clustering analysis. To obtain the proteins interacting with the hub targets, the STRING5 database was used, and the association score ā„0.9 was considered the highest confidence.
Pathway Enrichment Analysis
ClueGO (Version 2.3.2) () was utilized to analyze the representative biological processes and pathways associated with QLQX against CHF. All targets obtained from the CāT network were imported. GO biological process, Reactome pathway, and Wiki pathway were selected from the ClueGO setting panel, and a two-sided hypergeometric test with p ⤠0.01 significance level for biological process analysis and a p ⤠0.05 significance level for pathway analysis was used.
Cell Culture and Treatments
HCMECs were maintained in complete growth medium (90% H-DMEM, 10% FBS, and penicillin/streptomycin). All cells were cultured at 37°C in a humidified atmosphere containing 5% CO2. After three or four passages, the HCMECs were digested with 0.25% trypsin and adjusted to a density of 5 à 104 cells/ml and 1 à 105 cells/ml for cell viability assay and Western blot analysis, respectively. The powder of QLQX was accurately weighed and dissolved in complete growth medium to various concentrations (0.15 and 0.3 mg/ml). The cells used for cell viability assay were seeded on 96-well plates in 100 µl of complete growth medium (0.15 or 0.3 mg/ml QLQX were added) for 24, 48, or 72 h and were then treated with 10 mM Hcy for another 24 h. The cells used for Western blot analysis were divided into the following groups: control, model, positive-captopril (CA), QLQX-low (-L), and QLQX-high (-H). Cells in the control group were cultured without any treatments. In the model group, the HCMECs (1 à 105/ml) were cultured in 3 ml complete growth medium (10 mM Hcy was added) for 24 h. In the CA, -L, and -H groups, cells were pretreated with 0.075 mg/ml captopril, 0.15 mg/ml QLQX, and 0.3 mg/ml QLQX for 48 h, respectively, and then cultured in complete growth medium (10 mM Hcy was added) for a further 24 h.
Cell Viability Assay
Cell viability of the HCMECs was evaluated using the MTT assay. Cells were seeded on 96-well plates with a density of 5 à 104 cells/ml in 100 µl of complete growth medium (0.15 or 0.3 mg/ml QLQX were added) for 24, 48, or 72 h and were then treated with 10 mM Hcy for 24 h. Following treatment, 10 μl of MTT (5 mg/ml) was added to each well. After 4 h, the culture medium was removed, and 100 μl of dimethyl sulfoxide (Beyotime, Shanghai, China) was added. The absorbance was measured at 570 nm using a microplate reader (Infinite M200 Pro, Tecan, Switzerland), and the cell viability was expressed as a percentage of the value of the untreated group.
Western Blot Analysis
HCMECs (1 à 105 cells/ml) were seeded on 60 à 20-mm dishes in 3 ml of complete growth medium for 24 h. After treatment, the HCMECs were scraped off and washed twice with cold phosphate-buffered saline. The cells were solubilized by radioimmunoprecipitation assay lysis buffer (Beyotime, China) containing 1% phenylmethylsulphonyl fluoride (Beyotime, China) and 1% phosphatase inhibitor for 20 min on ice. Whole-cell lysates were clarified by centrifuging at 12,000 rpm for 10 min at 4°C, and the supernatants were collected. Protein concentrations were determined by the BCA protein assay. The protein samples were mixed with sodium dodecyl sulfate polyacrylamide gel electrophoresis sample loading buffer (Beyotime, China) and boiled at 100°C for 5 min. Equal concentrations of protein (2 mg/ml) were separated by electrophoresis on 10% sodium dodecyl sulphate polyacrylamide gels and were transferred onto polyvinylidene difluoride membranes. These membranes were soaked in 5% skimmed milk, and dissolved with TBST buffer (Tris Buffer Saline supplemented with 0.1% Tween-20) 5 times (15 min each time) to block nonspecific binding sites. The membranes were then incubated overnight at 4°C with the primary antibodies (VEGFA, STAT3, p-STAT3, JAK2, p-JAK2, IL-6, ADRB1, and ADRB2). After washing with TBST, the membranes were incubated for 2 h at room temperature with horseradish peroxidase-labeled secondary antibodies. After rewashing with TBST, the membranes were scanned using a fluorescent scanner (Odyssey CLX, Gene Company Limited, USA). Band intensity was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Statistical Analysis
Data were presented as mean ± SD and analyzed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). One-way analysis of variance (ANOVA) was used, and p-value < 0.05 was considered statistically significant.
Results
Pharmacokinetics Study of 29 Components in QLQX by HPLC-MS/MS
Pharmacokinetic properties of 29 components in QLQX (astragaloside, calycosin-7-glucoside, sinapine bisulfate, ginsenoside Rb1, Rb2, Rg1, Rg3, Rc, Rd, Re, Rf, F2, salvianolic acid A, salvianolic acid B, danshensu, lithospermic acid, rosmarinic acid, protocatechuic acid, hydroxysafflor yellow A, formononetin, hesperidin, rutin, quercetin, aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, and benzoylhypaconine) were studied using the HPLC-MS/MS method according to the method in our previous study (Zhang et al., 2018). The pharmacokinetic properties of 29 components are shown in Table 1, and the mean concentrationātime curves are shown in Figure 2. These 29 components of QLQX detected in the blood of the rats and with appropriate pharmacokinetic properties were determined to be the main active components and used to construct the CāT network.
Table 1
| No. | Compounds | Polarity | Parent (m/z) | Daughter (m/z) | Pharmacokinetic parameters | ||||
|---|---|---|---|---|---|---|---|---|---|
| Cmax | Tmax | t1/2 | AUC0ā¼t | AUC0ā¼ā | |||||
| 1 | Astragaloside | Positive | 807.5 | 627.3 | 120.46 ± 45.03 | 0.67 ± 0.00 | 5.74 ± 0.78 | 320.92 ± 79.10 | 369.14 ± 103.83 |
| 2 | Calycosin-7-glucoside | Positive | 447.2 | 285.2 | 31.49 ± 12.00 | 0.67 ± 0.06 | 6.05 ± 3.34 | 103.26 ± 47.63 | 120.71 ± 50.71 |
| 3 | Sinapine bisulfate | Positive | 310.2 | 251.2 | 1.35 ± 0.62 | 1.50 ± 0.00 | 3.52 ± 0.17 | 3.98 ± 1.21 | 8.76 ± 2.85 |
| 4 | Ginsenoside Rb1 | Positive | 1,131.7 | 365.2 | 323.00 ± 91.00 | 0.67 ± 0.00 | 9.16 ± 3.18 | 590.15 ± 257.83 | 713.49 ± 270.66 |
| 5 | Ginsenoside Rb2 | Positive | 1,107.8 | 335.0 | 31.25 ± 9.89 | 1.50 ± 0.06 | 10.11 ± 4.53 | 143.73 ± 35.67 | 307.99 ± 79.92 |
| 6 | Ginsenoside Rg1 | Positive | 823.5 | 643.5 | 113.44 ± 48.22 | 0.67 ± 0.00 | 8.69 ± 3.17 | 362.17 ± 118.25 | 422.31 ± 180.63 |
| 7 | Ginsenoside Rg3 | Positive | 807.6 | 364.9 | 20.49 ± 7.16 | 0.67 ± 0.24 | 5.03 ± 2.02 | 67.13 ± 27.93 | 89.81 ± 34.43 |
| 8 | Ginsenoside Rc | Positive | 1,101.6 | 789.5 | 180.00 ± 70.00 | 0.67 ± 0.00 | 4.32 ± 2.10 | 432.71 ± 178.66 | 493.04 ± 233.70 |
| 9 | Ginsenoside Rd | Positive | 969.5 | 789.6 | 97.49 ± 31.00 | 0.67 ± 0.00 | 5.90 ± 1.14 | 204.66 ± 87.30 | 257.92 ± 101.52 |
| 10 | Ginsenoside Re | Positive | 969.6 | 789.6 | 118.94 ± 52.82 | 0.67 ± 0.06 | 7.33 ± 3.45 | 268.84 ± 103.24 | 310.95 ± 147.36 |
| 11 | Ginsenoside Rf | Positive | 823.5 | 365.2 | 43.03 ± 12.49 | 0.67 ± 0.00 | 6.12 ± 3.53 | 130.27 ± 27.91 | 177.68 ± 68.95 |
| 12 | Ginsenoside F2 | Positive | 807.5 | 627.7 | 3.83 ± 1.23 | 0.67 ± 0.00 | 6.23 ± 2.89 | 12.73 ± 3.62 | 18.64 ± 5.28 |
| 13 | Salvianolic acid A | Negative | 493.1 | 294.9 | 8.96 ± 2.90 | 0.17 ± 0.00 | 7.50 ± 4.92 | 18.59 ± 7.91 | 21.40 ± 7.36 |
| 14 | Salvianolic acid B | Negative | 717.3 | 519.2 | 502.00 ± 68.43 | 0.33 ± 0.14 | 5.32 ± 1.32 | 818.47 ± 249.00 | 980.47 ± 112.07 |
| 15 | Danshensu | Negative | 196.9 | 134.8 | 98.60 ± 23.66 | 0.67 ± 0.00 | 3.52 ± 0.42 | 290.92 ± 68.38 | 390.90 ± 66.50 |
| 16 | Lithospermic acid | Negative | 537.4 | 493.2 | 77.25 ± 19.90 | 0.67 ± 0.00 | 4.80 ± 0.89 | 173.49 ± 38.57 | 216.94 ± 27.39 |
| 17 | Rosmarinic acid | Negative | 358.9 | 160.9 | 52.16 ± 5.96 | 0.67 ± 0.00 | 5.28 ± 1.35 | 78.65 ± 35.72 | 96.69 ± 24.81 |
| 18 | Protocatechuic acid | Negative | 152.9 | 108.8 | 17.00 ± 7.26 | 0.67 ± 0.00 | 8.38 ± 1.02 | 44.15 ± 18.02 | 61.03 ± 10.51 |
| 19 | Hydroxysafflor yellow A | Negative | 611.2 | 491.0 | 8.62 ± 3.51 | 0.17 ± 0.00 | 5.03 ± 2.00 | 15.63 ± 4.42 | 21.99 ± 6.25 |
| 20 | Formononetin | Negative | 266.9 | 251.7 | 5.17 ± 1.13 | 0.17 ± 0.00 | 5.07 ± 2.13 | 14.70 ± 5.48 | 18.04 ± 6.69 |
| 21 | Hesperidin | Negative | 609.2 | 300.9 | 64.63 ± 23.49 | 0.67 ± 0.00 | 3.34 ± 0.42 | 154.32 ± 66.50 | 187.77 ± 34.98 |
| 22 | Rutin | Negative | 609.2 | 299.6 | 3.63 ± 1.25 | 0.33 ± 0.00 | 5.33 ± 1.27 | 12.29 ± 2.47 | 16.92 ± 5.21 |
| 23 | Quercetin | Negative | 301.1 | 150.7 | 3.23 ± 1.26 | 0.67 ± 0.00 | 5.04 ± 0.98 | 10.96 ± 3.42 | 15.03 ± 5.28 |
| 24 | Aconitine | Positive | 646.4 | 586.4 | 1.44 ± 0.68 | 0.33 ± 0.00 | 18.35 ± 5.44 | 7.03 ± 2.31 | 18.16 ± 6.87 |
| 25 | Mesaconitine | Positive | 632.3 | 572.3 | 0.52 ± 0.16 | 0.17 ± 0.06 | 6.23 ± 1.23 | 3.95 ± 1.02 | 5.13 ± 2.32 |
| 26 | Hypaconitine | Positive | 616.3 | 556.3 | 1.97 ± 0.33 | 0.33 ± 0.00 | 8.01 ± 2.39 | 7.89 ± 2.57 | 13.85 ± 6.67 |
| 27 | Benzoylaconine | Positive | 604.2 | 554.3 | 1.83 ± 0.33 | 1.00 ± 0.00 | 18.63 ± 7.20 | 8.63 ± 2.39 | 25.94 ± 9.03 |
| 28 | Benzoylmesaconine | Positive | 590.2 | 540.3 | 5.84 ± 0.61 | 0.67 ± 0.11 | 8.23 ± 2.02 | 20.13 ± 6.27 | 35.34 ± 11.22 |
| 29 | Benzoylhypaconine | Positive | 574.2 | 542.3 | 0.67 ± 0.32 | 0.67 ± 0.00 | 12.88 ± 3.47 | 4.03 ± 1.03 | 7.80 ± 3.84 |
Pharmacokinetic properties of 29 components in QLQX determined by HPLC-MS/MS.
Figure 2
CompoundāTarget Network Construction
Totally, 1,288 targets were found for the 29 components using Drugbank, Swiss Target Prediction, and SEA databases. The detailed target information for the 29 components in QLQX is shown in Supplementary Table S1. A total of 812 candidate targets of CHF were obtained from DisGeNet and Drugbank databases after removing redundant entries (Supplementary Table S2). Taking the intersection of the 1,288 putative targets of the 29 components in QLQX and the 812 candidate targets associated with CHF, a total of 120 consensus targets were collected as potential therapeutic targets of QLQX against CHF and used to establish the CāT network. As a result, a CāT network comprising 29 components and 120 consensus targets was constructed using Cytoscape. As shown in Figure 3A, the network comprised 149 nodes (29 components and 120 targets) and 446 edges.
Figure 3
Network Topological Analysis
Network analyzer was used to calculate four topological features (degree, betweenness centrality, average shortest path length, and closeness centrality) of the nodes of the CāT network. Nodes with degrees higher than the average number of neighbors (5.830) were identified and extracted as the major hub networks (Figure 3B). Among these, 32 major targets with higher degree, closeness centrality, betweenness centrality, and lower average shortest path length were recognized as the major putative targets, and the results are shown in Table 2. Twenty-eight components were identified as the main active components (Table 3), and quercetin had the highest degree and betweenness centrality of 46 and 0.35, respectively, thereby indicating that quercetin has the most important position in the network.
Table 2
| Swiss prot | Genes/proteins | Description | Degree | Betweenness centrality | Average shortest path length | Closeness centrality |
|---|---|---|---|---|---|---|
| Q9Y6L6 | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | 12 | 0.09496758 | 2.69078947 | 0.37163814 |
| Q9NPD5 | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | 11 | 0.04862563 | 3.28289474 | 0.30460922 |
| P43166 | CA7 | Carbonic anhydrase 7 | 11 | 0.04690937 | 2.40131579 | 0.41643836 |
| P22748 | CA4 | Carbonic anhydrase 4 | 11 | 0.04164377 | 2.45394737 | 0.4075067 |
| P15692 | VEGFA | Vascular endothelial growth factor A | 11 | 0.11260667 | 2.79605263 | 0.35764706 |
| Q8TCC7 | SLC22A8 | Solute carrier family 22 member 8 | 10 | 0.03755913 | 3.23026316 | 0.3095723 |
| P15121 | AKR1B1 | Aldo-keto reductase family 1 member B | 10 | 0.02861805 | 2.70394737 | 0.36982968 |
| P08183 | ABCB1 | Multidrug resistance protein 1 | 10 | 0.06692038 | 2.67763158 | 0.37346437 |
| Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 9 | 4.74Eā04 | 4.08552632 | 0.24476651 |
| P46721 | SLCO1A2 | Solute carrier organic anion transporter family member 1A2 | 9 | 4.74Eā04 | 4.08552632 | 0.24476651 |
| P40763 | STAT3 | Signal transducer and activator of transcription 3 | 9 | 4.74Eā04 | 4.08552632 | 0.24476651 |
| P20813 | CYP2B6 | Cytochrome P450 2B6 | 9 | 4.74Eā04 | 4.08552632 | 0.24476651 |
| P10632 | CYP2C8 | Cytochrome P450 2C8 | 9 | 0.05421697 | 2.75657895 | 0.3627685 |
| P05023 | ATP1A1 | Sodium/potassium-transporting ATPase subunit alpha-1 | 9 | 4.74Eā04 | 4.08552632 | 0.24476651 |
| P04798 | CYP1A1 | Cytochrome P450 1A1 | 9 | 4.74Eā04 | 4.08552632 | 0.24476651 |
| P02766 | TTR | Transthyretin | 9 | 0.02882135 | 2.53289474 | 0.39480519 |
| P08684 | CYP3A4 | Cytochrome P450 3A4 | 8 | 0.01906502 | 3.15131579 | 0.31732777 |
| P07550 | ADRB2 | Beta-2 adrenergic receptor | 8 | 0.04366511 | 3.20394737 | 0.31211499 |
| P07451 | CA3 | Carbonic anhydrase 3 | 8 | 0.03416389 | 2.45394737 | 0.4075067 |
| Q9UNQ0 | ABCG2 | ATP binding cassette subfamily G member 2 (Junior blood group) | 7 | 0.0203742 | 2.74342105 | 0.36450839 |
| Q9ULX7 | CA14 | Carbonic anhydrase 14 | 7 | 0.02057174 | 2.625 | 0.38095238 |
| P31645 | SLC6A4 | Solute carrier family 6 member 4 | 7 | 0.0021531 | 3.83552632 | 0.26072041 |
| P23975 | SLC6A2 | Solute carrier family 6 member 2 | 7 | 0.0021531 | 3.83552632 | 0.26072041 |
| O43570 | CA12 | Carbonic anhydrase 12 | 7 | 0.01886671 | 2.66447368 | 0.37530864 |
| Q14524 | SCN5A | Sodium voltage-gated channel alpha subunit 5 | 6 | 1.51Eā04 | 4.09868421 | 0.24398074 |
| P24462 | CYP3A7 | Cytochrome P450 3A7 | 6 | 1.51Eā04 | 4.09868421 | 0.24398074 |
| P20815 | CYP3A5 | Cytochrome P450 3A5 | 6 | 1.51Eā04 | 4.09868421 | 0.24398074 |
| P10635 | CYP2D6 | Cytochrome P450 2D6 | 6 | 1.51Eā04 | 4.09868421 | 0.24398074 |
| P08588 | ADRB1 | Adrenoceptor beta 1 | 6 | 1.51Eā04 | 4.09868421 | 0.24398074 |
| P08254 | MMP3 | Matrix metallopeptidase 3 | 6 | 0.00514916 | 2.95394737 | 0.33853007 |
| P00918 | CA2 | Carbonic anhydrase 2 | 6 | 0.01628126 | 2.67763158 | 0.37346437 |
| O15244 | SLC22A2 | Solute carrier family 22 member 2 | 6 | 1.51Eā04 | 4.09868421 | 0.24398074 |
The topological parameters of 32 major targets.
Table 3
| No. | Compounds | Degree | Betweenness centrality | Average shortest path length | Closeness centrality |
|---|---|---|---|---|---|
| QLQX-23 | Quercetin | 46 | 0.34943416 | 2.21052632 | 0.45238095 |
| QLQX-20 | Formononetin | 37 | 0.20139204 | 2.47368421 | 0.40425532 |
| QLQX-15 | Danshensu | 27 | 0.14738861 | 2.85526316 | 0.35023041 |
| QLQX-18 | Protocatechuic acid | 25 | 0.14911094 | 2.65789474 | 0.37623762 |
| QLQX-21 | Hesperidin | 22 | 0.10590127 | 2.71052632 | 0.36893204 |
| QLQX-3 | Sinapine bisulfate | 18 | 0.06332468 | 2.94736842 | 0.33928571 |
| QLQX-17 | Rosmarinic acid | 18 | 0.05489072 | 2.96052632 | 0.33777778 |
| QLQX-22 | Rutin | 15 | 0.03964651 | 2.98684211 | 0.33480176 |
| QLQX-1 | Astragaloside | 15 | 0.13507408 | 3.44736842 | 0.29007634 |
| QLQX-29 | Benzoylhypaconine | 15 | 0.02499921 | 3.17105263 | 0.3153527 |
| QLQX-27 | Benzoylaconine | 14 | 0.0210363 | 3.18421053 | 0.31404959 |
| QLQX-26 | Hypaconitine | 14 | 0.0210363 | 3.18421053 | 0.31404959 |
| QLQX-7 | Ginsenoside Rg3 | 13 | 0.03221083 | 3.19736842 | 0.3127572 |
| QLQX-13 | Salvianolic acid A | 13 | 0.0102585 | 3.19736842 | 0.3127572 |
| QLQX-28 | Benzoylmesaconine | 13 | 0.01850138 | 3.19736842 | 0.3127572 |
| QLQX-25 | Mesaconitine | 13 | 0.01786266 | 3.19736842 | 0.3127572 |
| QLQX-24 | Aconitine | 13 | 0.01786266 | 3.19736842 | 0.3127572 |
| QLQX-16 | Lithospermic acid | 12 | 0.00961587 | 3.21052632 | 0.31147541 |
| QLQX-8 | Ginsenoside Rc | 11 | 0.01141274 | 3.22368421 | 0.31020408 |
| QLQX-4 | Ginsenoside Rb1 | 11 | 0.01141274 | 3.22368421 | 0.31020408 |
| QLQX-9 | Ginsenoside Rd | 10 | 0.0092025 | 3.23684211 | 0.30894309 |
| QLQX-6 | Ginsenoside Rg1 | 10 | 0.0092025 | 3.23684211 | 0.30894309 |
| QLQX-5 | Ginsenoside Rb2 | 10 | 0.0092025 | 3.23684211 | 0.30894309 |
| QLQX-12 | Ginsenoside F2 | 10 | 0.0092025 | 3.23684211 | 0.30894309 |
| QLQX-11 | Ginsenoside Rf | 10 | 0.0092025 | 3.23684211 | 0.30894309 |
| QLQX-10 | Ginsenoside Re | 10 | 0.0092025 | 3.23684211 | 0.30894309 |
| QLQX-14 | Salvianolic acid b | 9 | 0.0045723 | 3.25 | 0.30769231 |
| QLQX-19 | Hydroxysafflor yellow a | 7 | 0.01639755 | 3.09210526 | 0.32340426 |
The topological parameters of 28 main active components.
Clustering Analysis
MCODE was used to identify the major hubs of QLQX against CHF, which generated a well-organized cluster containing 17 nodes (SLC22A8, SLCO1B3, QLQX-9, QLQX-11, QLQX-5, QLQX-8, CYP1A1, QLQX-12, QLQX-6, ATP1A1, VEGFA, CYP2B6, STAT3, SLCO1A2, QLQX-10, QLQX-4, and STAT4). Taking the intersection of the topological analysis and clustering analysis results, a total of nine consensus targets were collected to be hub targets of QLQX against CHF, namely, SLC22A8, SLCO1B3, CYP1A1, ATP1A1, VEGFA, CYP2B6, STAT3, SLCO1A2, and STAT4. Then, the nine consensus targets were used as hub targets and submitted to STRING to generate the proteins interacting with these hub targets. The STRING database provides both experimental and predicted interaction information and provides a probabilistic association confidence score by calculation. As shown in Table 4, six target genes, namely, VEGFA, CYP1A1, CYP2B6, ATP1A1, STAT3, and STAT4, and 10 predicted functional genes, namely, KDR, FLT1, NRP2, JAK2, EGFR, IL-6, AHR, ATP1B1, JAK1, and HIF1A, having the highest confidence with an association score ā„0.9 were imported into Cytoscape 3.2.1 (Figure 3C). The network analysis tool was used to analyze the PPI network and targets with a higher degree played an important role in central correlation. The results are shown in Table 5.
Table 4
| Node 1 | Interaction | Node 2 | Score |
|---|---|---|---|
| VEGFA | pp | KDR | 0.999 |
| VEGFA | pp | FLT1 | 0.999 |
| VEGFA | pp | NRP2 | 0.998 |
| JAK2 | pp | STAT3 | 0.998 |
| EGFR | pp | STAT3 | 0.998 |
| CYP1A1 | pp | AHR | 0.997 |
| JAK1 | pp | STAT3 | 0.997 |
| ATP1A1 | pp | ATP1B1 | 0.997 |
| IL6 | pp | STAT3 | 0.997 |
| VEGFA | pp | HIF1A | 0.996 |
| VEGFA | pp | STAT3 | 0.994 |
| NRP2 | pp | FLT1 | 0.988 |
| FLT1 | pp | KDR | 0.988 |
| HIF1A | pp | STAT3 | 0.986 |
| STAT4 | pp | JAK2 | 0.984 |
| NRP2 | pp | KDR | 0.983 |
| STAT4 | pp | JAK1 | 0.983 |
| VEGFA | pp | EGFR | 0.979 |
| IL6 | pp | JAK2 | 0.975 |
| HIF1A | pp | EGFR | 0.973 |
| IL6 | pp | JAK1 | 0.968 |
| JAK1 | pp | EGFR | 0.966 |
| VEGFA | pp | IL6 | 0.959 |
| JAK2 | pp | JAK1 | 0.943 |
| STAT4 | pp | STAT3 | 0.938 |
| JAK2 | pp | EGFR | 0.928 |
| CYP1A1 | pp | CYP2B6 | 0.928 |
| IL6 | pp | EGFR | 0.921 |
The proteins interacting of hub targets.
Table 5
| Genes/proteins | Degree | Betweenness centrality | Average shortest path length | Closeness centrality |
|---|---|---|---|---|
| VEGFA | 7 | 0.47407407 | 1.3 | 0.76923077 |
| STAT3 | 7 | 0.21481481 | 1.3 | 0.76923077 |
| EGFR | 6 | 0.08888889 | 1.4 | 0.71428571 |
| JAK2 | 5 | 0.01481481 | 1.8 | 0.55555556 |
| JAK1 | 5 | 0.01481481 | 1.8 | 0.55555556 |
| IL6 | 5 | 0.05925926 | 1.5 | 0.66666667 |
| KDR | 3 | 0 | 2 | 0.5 |
| FLT1 | 3 | 0 | 2 | 0.5 |
| NRP2 | 3 | 0 | 2 | 0.5 |
| HIF1A | 3 | 0 | 1.7 | 0.58823529 |
| STAT4 | 3 | 0 | 2 | 0.5 |
| CYP1A1 | 2 | 1 | 1 | 1 |
| AHR | 1 | 0 | 1.5 | 0.66666667 |
| ATP1A1 | 1 | 0 | 1 | 1 |
| ATP1B1 | 1 | 0 | 1 | 1 |
| CYP2B6 | 1 | 0 | 1.5 | 0.66666667 |
The topological parameters of PPI network.
Pathway Enrichment Analysis
To analyze the representative biological processes and pathways associated with the 120 targets of the CāT network, GO biological, Reactome, and Wiki pathway analysis were used to explore the potential biological processes and pathways affected by QLQX through analysis of the 120 targets. The biological processes were ranked by their nominal P values with a cutoff at 0.01, and 120 targets were enriched to 26 biological processes; the top 10 are shown in Supplementary Table S3 and Figure 4A. The pathways were ranked by their nominal p values with a cutoff at 0.05, and the top 10 pathways included interleukin-4 and 13 signaling, phase I functionalization of compounds, drug induction of bile acid pathway, xenobiotics, tamoxifen metabolism, reversible hydration of carbon dioxide, electron transport chain, adrenoceptors, adenosine P1 receptors, and angiotensin-converting enzyme inhibitor pathway (Figure 4B). The functional targets involved in each pathway are illustrated in Supplementary Table S4. The CāT pathway/biological process network (CāTāP) was constructed using Cytoscape (Figure 5) based on the interactions among the 29 components, 120 consensus targets, and top 10 biological processes and pathways.
Figure 4
Figure 5
Experimental Validation of Key Targets and Pathway
MTT assays showed that 0.15 (-L) and 0.3 mg/ml (-H) QLQX dramatically inhibited Hcy-induced injury in the HCMEC at 48 and 72 h in a time-dependent manner (Figure 6). To determine the mechanisms of QLQX in the treatment of CHF, some of the key proteins with a higher degree in the PPI network were experimentally validated in the HCMEC. Besides, considering that ADRB1 and ADRB2 play an essential role in heart failure (; ), ADRB1 and ADRB2 were used as a control to validate the effect of QLQX. As shown in Figure 6, QLQX significantly increased the ratio between ADRB1 and ADRB2. Meanwhile, QLQX significantly increased the expression level of VEGFA and inhibited the expression levels of p-STAT3, p-JAK2, and IL-6 in a dose-dependent manner.
Figure 6
Discussion
As a multicomponent drug, QLQX has been used for several years to treat CHF in China and has been demonstrated as effective in lowering the NT-proBNP level in CHF patients (). However, its āmulticompound, multitargetā characteristics make it difficult to decipher the active ingredients and mechanisms of QLQX in the treatment against CHF.
Integrated strategies based on network pharmacology provide a useful approach to investigate the active components and molecular mechanisms. For instance, proposed a āmain active compound-based network pharmacologyā based on quantitative analysis of components to explore the anticancer mechanism of CKI. They selected herbs used in the clinical therapy of hepatoma to ascertain molecular targets and antitumor mechanisms, emphasizing the combination of clinical study and network pharmacology. However, in previous studies, all herbal ingredients were collected from herb databases and filtered according to absorption, distribution, metabolism, and excretion properties or drug-likeness value, which may be inconsistent with the ingredients present in the blood (). Here, we proposed an integrated strategy via pharmacokinetics study, network analysis, and experimental validation to achieve an accurate and systematic exploration of the mechanisms of QLQX against CHF.
In this study, the 29 components of QLQX showing proper pharmacokinetics behavior in rats were determined to be the active ingredients of QLQX. These compounds were mainly categorized as triterpenoid saponins, phenolic acids, flavonoids, and alkaloids. Particularly, astragaloside, ginsenoside Rb1, Rb2, Rg1, Rg3, Rc, Rd, Re, Rf, and ginsenoside F2, as triterpenoid saponins, are known for their anti-inflammatory property during the period of ventricular remodeling (; ); salvianolic acid A, salvianolic acid B, danshensu, lithospermic acid, rosmarinic acid, and protocatechuic acid, as phenolic acids, exert cardioprotection through promoting angiogenesis in animal models (Yu et al., 2017); calycosin-7-glucoside, hydroxysafflor yellow A, formononetin, hesperidin, rutin, and quercetin, as flavonoids, can reduce cardiomyocytes damage and apoptosis and improve cardiac function by decreasing oxidative stress (); and aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, benzoylhypaconine, and sinapine bisulfate, as alkaloids, can improve left ventricular systolic and diastolic function (). Moreover, the hub targets of these active ingredients were determined via combining network topological parameters with clustering and PPI network analysis. In total, 6 targets, namely, VEGFA, CYP1A1, CYP2B6, ATP1A1, STAT3, and STAT4, and 10 predicted functional targets, namely, KDR, FLT1, NRP2, JAK2, EGFR, IL-6, AHR, ATP1B1, JAK1, and HIF1A were collected as hub targets of QLQX against CHF.
As the leading cause of cardiovascular mortality, CHF is associated with many pathogenic factors, such as increased hemodynamic overload, ventricular remodeling, neurohormonal activation, and energy metabolism disorder (; Tanai and Frantz, 2015). In recent years, increasing evidence has shown that cardiac microvascular and microcirculation functions are closely related, in that, proper cardiac function requires myocardial oxygen balance. Furthermore, the perturbations in microcirculation caused by the interplay of neurohumoral, metabolic, and endothelium-derived factors lead to cardiac microvascular dysfunction and further result in cardiac insufficiency or heart failure (; ).
It is thought that the presence of endothelial dysfunction, which induced by impairment of endothelium-dependent relaxation of blood vessels, might contributed to the pathogenesis of heart failure (). Previous study have suggested that Hcy could initiate mitochondrial dysfunction, which contributes to the cell apoptosis and chronic inflammation, thereby resulting in endothelial dysfunction (; Zhang et al., 2017). In this manuscript, the Hcy-induced HCMECs injury was used as the model to explore the role of QLQX in endothelial dysfunction of damaged microvascular endothelial cell. It has been shown that, captopril, as a positive control drug to treat HCMEC in our study, improves endothelium-dependent vasodilatation in patients with CHF (). Meanwhile, captopril can increase vascular endothelial growth factor (VEGFA) expression during the period of pathological angiogenesis and rarefaction and inhibit proinflammatory cytokine expression (IL-1β, IL-6, and IL-8) in cultured human coronary artery endothelial cells (; ). Studies have also reported that captopril exerted a cardioprotective effect on heart failure by inhibiting phosphorylation of JAK2/STAT3 (Zhang Y. et al., 2019).
We have shown that QLQX dramatically inhibited Hcy-induced injury on the HCMEC in a time-dependent manner as observed through MTT assays. Western blotting confirmed that QLQX significantly increased the ratio between ADRB1 and ADRB2, upregulated the expression level of VEGFA, and downregulated the expression levels of p-STAT3, p-JAK2, and IL-6 in Hcy-induced HCMEC. Evidence has shown that a reduction in the ADRB1/ADRB2 ratio has been observed in heart failure, and the use of adrenoceptor beta blockers is a cornerstone of current heart failure therapy (; Woo et al., 2015). Consistent with prior study, we validated the effect of QLQX on the expression of adrenoceptor beta, which showed the prediction power in network pharmacological analysis of our study. On this basis, CHF is defined by cardiac dysfunction associated with ventricular remodeling, and, more recently, an imbalance between angiogenesis and cardiac hypertrophy has increasingly been acknowledged as an additional contributing mechanism (Taimeh et al., 2013). Accordingly, the therapeutic effect of myocardial angiogenesis is emerging as a promising approach for the prevention and treatment of CHF (Vila et al., 2008; ). VEGFA, a cornerstone cytokine of angiogenesis, participates in the process of vascular remodeling and myocardial angiogenesis in CHF through maintenance and repair of luminal endothelium (). Besides, increased expression of VEGFA levels has been associated with the process of angiogenesis, and it may be adopted as an indicator of revascularization (; Wang et al., 2017; Yan et al., 2019).
As shown in the present study, QLQX exerts a protective effect against IL-6 secretion induced by Hcy in the HCMEC, which may be associated with negative regulation of the Janus kinase signal transducer and signal transduction activator of transcription (JAK-STAT) signaling. Recent evidence has revealed that inflammation is a critical pathological process of CHF (; ; ) and high levels of IL-6, a proinflammatory cytokine, have been reported to be an important mediator in chronic inflammatory and cardiovascular disorders (; ). Moreover, IL-6 exerts its action through a specific IL-6R and a soluble IL-6 receptor, whereby the IL-6/IL-6R complex binds to the membrane glycoprotein 130 to induce intracellular signaling pathways (; ). The JAK-STAT pathway is a characteristic signal transduction pathway that plays a crucial role in this process (). Specifically, the activated JAK2, a key member of the Janus family of kinases, leads to phosphorylation and activation of a group of transcription factors collectively called STATs. Among them, STAT3 also appears to be involved in a broad range of cytoprotection activities, such as inflammation, angiogenesis, extracellular matrix composition, and apoptosis in the heart (). Previous study has implicated astragaloside could improve vascular endothelial dysfunction induced by hyperglycemia by increasing eNOS expression and decreasing the content of IL-6 (). Evidence provided by showed calycosin protected vascular endothelial from LPS-induced endothelial injury through suppression of ROS and VEGFA level. Furthermore, it has been reported that salvianolic acid A inhibited endothelial dysfunction and vascular remodeling in spontaneously hypertensive rats (Teng et al., 2016). All these mentioned above suggest that some compounds in QLQX exerts a protective effect on vascular endothelial, which in another way could support the results in our study.
Therefore, we focused on the inflammation in the HCMEC, as we were interested in the role of the JAK/STAT signaling in the pathogenesis of QLQX against CHF. Inflammatory processes and angiogenesis may be interrelated during the process of CHF, and the angiogenesis factor promotes angiogenesis mainly through signaling pathways, of which JAK2-STAT3 is one of the important ones (). It was reported that inflammation and neovascularization in atheromatous plaques might be mediated by VEGFA (), and the antihuman IL-6 receptor monoclonal antibody was shown to improve endothelial function in patients with acute coronary syndromes (). Thus, QLQX can rectify the injury of microvascular endothelial cells induced by Hcy while significantly decreasing the levels of IL-6, p-JAK2, and p-STAT3, which suggests that QLQX may inhibit inflammatory processes and promote angiogenesis in CHF via the JAK/STAT signaling pathway.
Conclusion
In the current study, an integrated strategy was used to illustrate the active ingredients and molecular mechanisms of QLQX in the treatment of CHF by adopting pharmacokinetics study, network pharmacological analysis, and experimental validation. In total, 29 ingredients determined by pharmacokinetics study, instead of herb databases, were used for network pharmacology analysis. Through experimental validation of the hub targets (VEGFA, IL-6, p-STAT3, and p-JAK2), the JAK/STAT signaling pathway was identified as the mechanism of QLQX against inflammatory process in CHF. Additionally, the established CāTāP network remained a characteristic of multilink and multilevel comprehensive effects of QLQX. These results provided an efficient way to understand the pharmacological mechanisms of traditional Chinese medicine prescriptions.
Funding
This work was supported by the National Natural Science Foundation of China (81774227), Natural Science Fund of Tianjin City (17JCZDJC34600), Project of TCM and combining TCM and western medicine of Tianjin Health and Family Planning Committee (2015050), and Technology program in key areas of Tianjin (20190101).
Statements
Data availability statement
The data used to support the findings of this study are available from the corresponding author upon request.
Ethics statement
The animal study was reviewed and approved by the Ethics Committee of Tianjin University of Traditional Chinese Medicine (Tianjin, China). This study was carried out in accordance with the principles of the Basel Declaration and recommendations of guidelines of the National Institutes of Health.
Author contributions
YZ is the first author and performed all the experiments and drafted the manuscript. MZ revised the manuscript. FZ and SZ helped the first author and prepared the materials of this paper. WD and XX contributed toward study design, experimental setup, results supervision, and manuscript correction.
Acknowledgments
The authors would like to acknowledge the technical supports to Yan Wang from Tianjin University of Traditional Chinese Medicine.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019.01046/full#supplementary-material
References
1
AssenovY.RamirezF.SchelhornS. E.LengauerT.AlbrechtM. (2008). Computing topological parameters of biological networks. Bioinformatics24, 282ā284. doi: 10.1093/bioinformatics/btm554
2
AyoubK. F.PothineniN.RutlandJ.DingZ.MehtaJ. L. (2017). Immunity, inflammation, and oxidative stress in heart failure: emerging molecular targets. Cardiovasc. Drugs Ther.31, 593ā608. doi: 10.1007/s10557-017-6752-z
3
BacchiegaB. C.BacchiegaA. B.UsnayoM. J.BedirianR.SinghG.PinheiroG. D. (2017). Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. J. Am. Heart Assoc.6, e005038. doi: 10.1161/JAHA.116.005038
4
BaderG. D.HogueC. W. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinf.4, 2. doi: 10.1186/1471-2105-4-2
5
BakerA. J. (2014). Adrenergic signaling in heart failure: a balance of toxic and protective effects. Pflugers Arch.466, 1139ā1150. doi: 10.1007/s00424-014-1491-5
6
ChaoJ.DaiY.VerpoorteR.LamW.ChengY. C.PaoL. H.et al. (2017). Major achievements of evidence-based traditional Chinese medicine in treating major diseases. Biochem. Pharmacol.139, 94ā104. doi: 10.1016/j.bcp.2017.06.123
7
ChenF.WuJ. L.FuG. S.MouY.HuS. J. (2015). Chronic treatment with Qiliqiangxin ameliorates aortic endothelial cell dysfunction in diabetic rats. J. Cardiovasc. Pharmacol. Ther.20, 230ā240. doi: 10.1177/1074248414537705
8
CoccoG.JerieP.AmietP.PandolfiS. (2017). Inflammation in heart failure: known knowns and unknown unknowns. Expert Opin. Pharmacother.18, 1225ā1233. doi: 10.1080/14656566.2017.1351948
9
Den UilC. A.KlijnE.LagrandW. K.BrugtsJ. J.InceC.SpronkP. E.et al. (2008). The microcirculation in health and critical disease. Prog. Cardiovasc. Dis.51, 161ā170. doi: 10.1016/j.pcad.2008.07.002
10
DickS. A.EpelmanS. (2016). Chronic heart failure and inflammation: what do we really know? Circ. Res.119, 159ā176. doi: 10.1161/CIRCRESAHA.116.308030
11
DoughtyR. N.SharpeN. (1997). Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results. Annu. Rev. Med.48, 103ā114. doi: 10.1146/annurev.med.48.1.103
12
DrexlerH.KurzS.JeserichM.MunzelT.HornigB. (1995). Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am. J. Cardiol.76, 13Eā18E. doi: 10.1016/S0002-9149(99)80497-4
13
EnginH. B.GursoyA.NussinovR.KeskinO. (2014). Network-based strategies can help mono- and poly-pharmacology drug discovery: a systems biology view. Curr. Pharm. Des.20, 1201ā1207. doi: 10.2174/13816128113199990066
14
FujioY.MaedaM.MohriT.ObanaM.IwakuraT.HayamaA.et al. (2011). Glycoprotein 130 cytokine signal as a therapeutic target against cardiovascular diseases. J. Pharmacol. Sci.117, 213ā222. doi: 10.1254/jphs.11R05CR
15
FungF. Y.LinnY. C. (2015). Developing traditional Chinese medicine in the era of evidence-based medicine: current evidences and challenges. Evid. Based Complement Altern. Med.2015, 425037. doi: 10.1155/2015/425037
16
GaoL.WangK. X.ZhouY. Z.FangJ. S.QinX. M.DuG. H. (2018). Uncovering the anticancer mechanism of compound Kushen injection against HCC by integrating quantitative analysis, network analysis and experimental validation. Sci. Rep.8, 624. doi: 10.1038/s41598-017-18325-7
17
GaoL.WangX. D.NiuY. Y.DuanD. D.YangX.HaoJ.et al. (2016). Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology. Sci. Rep.6, 24944. doi: 10.1038/srep24944
18
GedelaM.KhanM.JonssonO. (2015). Heart Failure. S D Med68, 403ā405, 407ā409. doi: 10.1056/NEJMra021498
19
GreeneA. S.AmaralS. L. (2002). Microvascular angiogenesis and the renināangiotensin system. Curr. Hypertens. Rep.4, 56ā62. doi: 10.1007/s11906-002-0054-x
20
HaasM. J.Jurado-FloresM.HammoudR.FengV.GonzalesK.Onstead-HaasL.et al. (2019). The effects of known cardioprotective drugs on proinflammatory cytokine secretion from human coronary artery endothelial cells. Am. J. Ther.26, e321āe332. doi: 10.1097/MJT.0000000000000648
21
HanS.WuH.LiW.GaoP. (2015). Protective effects of genistein in homocysteine-induced endothelial cell inflammatory injury. Mol. Cell. Biochem.403, 43ā49. doi: 10.1007/s11010-015-2335-0
22
HeinonenI.SoropO.de BeerV. J.DunckerD. J.MerkusD. (2015). What can we learn about treating heart failure from the heartās response to acute exercise? Focus on the coronary microcirculation. J. Appl. Physiol. (1985)119, 934ā943. doi: 10.1152/japplphysiol.00053.2015
23
HirotaH.IzumiM.HamaguchiT.SugiyamaS.MurakamiE.KunisadaK.et al. (2004). Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels19, 237ā241. doi: 10.1007/s00380-004-0770-z
24
HolteE.KlevelandO.UelandT.KunsztG.BratlieM.BrochK.et al. (2017). Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart103, 1521ā1527. doi: 10.1136/heartjnl-2016-310875
25
HuangP.KeH.QiuY.CaiM.QuJ.LengA. (2019). Systematically characterizing chemical profile and potential mechanisms of Qingre Lidan decoction acting on cholelithiasis by integrating UHPLC-QTOF-MS and network target analysis. Evid. Based Complement Altern. Med.2019, 2675287. doi: 10.1155/2019/2675287
26
JiangY. H.SunW.LiW.HuH. Z.ZhouL.JiangH. H.et al. (2015). Calycosin-7-O-beta-D-glucoside promotes oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cells. BMC Complement Altern. Med.15, 315. doi: 10.1186/s12906-015-0839-5
27
KishimotoS.KajikawaM.MaruhashiT.IwamotoY.MatsumotoT.IwamotoA.et al. (2017). Endothelial dysfunction and abnormal vascular structure are simultaneously present in patients with heart failure with preserved ejection fraction. Int. J. Cardiol.231, 181ā187. doi: 10.1016/j.ijcard.2017.01.024
28
KucukardaliY.AydogduS.OzmenN.YonemA.SolmazgulE.OzyurtM.et al. (2008). The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor. Cardiovasc. Revasc. Med.9, 66ā70. doi: 10.1016/j.carrev.2007.11.005
29
LengB.TangF.LuM.ZhangZ.WangH.ZhangY. (2018). Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-kappaB signaling pathway. Life Sci.209, 111ā121. doi: 10.1016/j.lfs.2018.07.053
30
LiS.ZhangB. (2013). Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin. J. Nat. Med.11, 110ā120. doi: 10.1016/S1875-5364(13)60037-0
31
LiX.ZhangJ.HuangJ.MaA.YangJ.LiW.et al. (2013). A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J. Am. Coll. Cardiol.62, 1065ā1072. doi: 10.1016/j.jacc.2013.05.035
32
LiY.WangY.TaiW.YangL.ChenY.ChenC.et al. (2015). Challenges and solutions of pharmacokinetics for efficacy and safety of traditional Chinese medicine. Curr. Drug Metab.16, 765ā776. doi: 10.2174/138920021609151201114223
33
LiuX. X.JianX. X.CaiX. F.ChaoR. B.ChenQ. H.ChenD. L.et al. (2012). Cardioactive C(1)(9)-diterpenoid alkaloids from the lateral roots of Aconitum carmichaeliāFu Ziā. Chem. Pharm. Bull. (Tokyo)60, 144ā149. doi: 10.1248/cpb.60.144
34
MatteraR.BenvenutoM.GigantiM.G.TresoldiI.PluchinottaF.R.BerganteS.et al. (2017). Effects of polyphenols on oxidative stress-mediated injury in cardiomyocytes. Nutrients9, 523. doi: 10.3390/nu9050523
35
MiN.ChengT.LiH.YangP.MuX.WangX.et al. (2019). Metabolite profiling of traditional Chinese medicine formula Dan Zhi Tablet: an integrated strategy based on UPLC-QTOF/MS combined with multivariate statistical analysis. J. Pharm. Biomed. Anal.164, 70ā85. doi: 10.1016/j.jpba.2018.10.024
36
MohriT.IwakuraT.NakayamaH.FujioY. (2012). JAK-STAT signaling in cardiomyogenesis of cardiac stem cells. JAKSTAT1, 125ā130. doi: 10.4161/jkst.20296
37
MorineK. J.ParuchuriV.QiaoX.MohammadN.McgrawA.YunisA.et al. (2016). Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis. Biomarkers21, 91ā97. doi: 10.3109/1354750X.2015.1118539
38
MoultonK. S.VakiliK.ZurakowskiD.SolimanM.ButterfieldC.SylvinE.et al. (2003). Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. U. S. A.100, 4736ā4741. doi: 10.1073/pnas.0730843100
39
NingZ.WangC.LiuY.SongZ.MaX.LiangD.et al. (2018). Integrating strategies of herbal metabolomics, network pharmacology, and experiment validation to investigate frankincense processing effects. Front. Pharmacol.9, 1482. doi: 10.3389/fphar.2018.01482
40
OkaT.AkazawaH.NaitoA. T.KomuroI. (2014). Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ. Res.114, 565ā571. doi: 10.1161/CIRCRESAHA.114.300507
41
ParkS. Y.ParkJ. H.KimH. S.LeeC. Y.LeeH. J.KangK. S.et al. (2018). Systems-level mechanisms of action of Panax ginseng: a network pharmacological approach. J. Ginseng Res.42, 98ā106. doi: 10.1016/j.jgr.2017.09.001
42
Ptaszynska-KopczynskaK.SzpakowiczA.Marcinkiewicz-SiemionM.LisowskaA.WaszkiewiczE.WitkowskiM.et al. (2017). Interleukin-6 signaling in patients with chronic heart failure treated with cardiac resynchronization therapy. Arch. Med. Sci.13, 1069ā1077. doi: 10.5114/aoms.2016.58635
43
QiY.GaoF.HouL.WanC. (2017). Anti-inflammatory and immunostimulatory activities of astragalosides. Am. J. Chin. Med.45, 1157ā1167. doi: 10.1142/S0192415X1750063X
44
RubinovM.SpornsO. (2010). Complex network measures of brain connectivity: uses and interpretations. Neuroimage52, 1059ā1069. doi: 10.1016/j.neuroimage.2009.10.003
45
Shen-OrrS. S.FurmanD.KiddB. A.HadadF.LovelaceP.HuangY. W.et al. (2016). Defective signaling in the JAK-STAT pathway tracks with chronic inflammation and cardiovascular risk in aging humans. Cell Syst.3, 374ā384.e4. doi: 10.1016/j.cels.2016.09.009
46
SmartN.MojetM. H.LatchmanD. S.MarberM. S.DuchenM. R.HeadsR. J. (2006). IL-6 induces PI3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc. Res.69, 164ā177. doi: 10.1016/j.cardiores.2005.08.017
47
SmootM. E.OnoK.RuscheinskiJ.WangP. L.IdekerT. (2011). Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics27, 431ā432. doi: 10.1093/bioinformatics/btq675
48
SpadariR. C.CavadasC.de CarvalhoA.OrtolaniD.de MouraA. L.VassaloP. F. (2018). Role of beta-adrenergic receptors and sirtuin signaling in the heart during aging, heart failure, and adaptation to stress. Cell. Mol. Neurobiol.38, 109ā120. doi: 10.1007/s10571-017-0557-2
49
SunJ.ZhangK.XiongW. J.YangG. Y.ZhangY. J.WangC. C.et al. (2016). Clinical effects of a standardized Chinese herbal remedy, Qili Qiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis. BMC Complement Altern. Med.16, 201. doi: 10.1186/s12906-016-1174-1
50
SunY.LiuY.ChenK. (2016). Roles and mechanisms of ginsenoside in cardiovascular diseases: progress and perspectives. Sci. China Life Sci.59, 292ā298. doi: 10.1007/s11427-016-5007-8
51
TaimehZ.LoughranJ.BirksE.J.BolliR. (2013). Vascular endothelial growth factor in heart failure. Nat. Rev. Cardiol. 10, 519ā530. doi: 10.1038/nrcardio.2013.94
52
TanaiE.FrantzS. (2015). Pathophysiology of heart failure. Compr. Physiol.6, 187ā214. doi: 10.1002/cphy.c140055
53
TangW.HuangY. (2013). Cardiotonic modulation in heart failure: insights from traditional Chinese medicine. J. Am. Coll. Cardiol.62, 1073ā1074. doi: 10.1016/j.jacc.2013.05.028
54
TengF.YinY.CuiY.DengY.LiD.ChoK.et al. (2016). Salvianolic acid A inhibits endothelial dysfunction and vascular remodeling in spontaneously hypertensive rats. Life Sci.144, 86ā93. doi: 10.1016/j.lfs.2015.06.010
55
TingtingH.GuangzhongL.YanxiangZ.DongDongY.LiS.LiW. (2019). Qiliqiangxin attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in rabbits. Naunyn. Schmiedebergs Arch. Pharmacol.392, 585ā592. doi: 10.1007/s00210-018-01611-0
56
VilaV.Martinez-SalesV.AlmenarL.LazaroI. S.VillaP.ReganonE. (2008). Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. Int. J. Cardiol.130, 276ā277. doi: 10.1016/j.ijcard.2007.07.010
57
WangY.HuangQ.LiuJ.WangY.ZhengG.LinL.et al. (2017). Vascular endothelial growth factor A polymorphisms are associated with increased risk of coronary heart disease: a meta-analysis. Oncotarget8, 30539ā30551. doi: 10.18632/oncotarget.15546
58
WooA. Y.SongY.XiaoR. P.ZhuW. (2015). Biased beta2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br. J. Pharmacol.172, 5444ā5456. doi: 10.1111/bph.12965
59
XingX.ChenS.LiL.CaoY.ChenL.WangX.et al. (2018). The active components of Fuzheng Huayu Formula and their potential mechanism of action in inhibiting the hepatic stellate cells viabilityāa network pharmacology and transcriptomics approach. Front. Pharmacol.9, 525. doi: 10.3389/fphar.2018.00525
60
YanP.SunC.MaJ.JinZ.GuoR.YangB. (2019). MicroRNA-128 confers protection against cardiac microvascular endothelial cell injury in coronary heart disease via negative regulation of IRS1. J. Cell. Physiol. 8, 13452ā13463. doi: 10.1002/jcp.28025
61
YuL. J.ZhangK. J.ZhuJ. Z.ZhengQ.BaoX. Y.ThapaS.et al. (2017). Salvianolic acid exerts cardioprotection through promoting angiogenesis in animal models of acute myocardial infarction: preclinical evidence. Oxid. Med. Cell. Longev.2017, 8192383. doi: 10.1155/2017/8192383
62
YuanH.MaQ.CuiH.LiuG.ZhaoX.LiW.et al. (2017). How can synergism of traditional medicines benefit from network pharmacology? Molecules22, 1135. doi: 10.3390/molecules22071135
63
YunW. J.YaoZ. H.FanC. L.QinZ. F.TangX. Y.GaoM. X.et al. (2018). Systematic screening and characterization of Qi-Li-Qiang-Xin capsule-related xenobiotics in rats by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.1090, 56ā64. doi: 10.1016/j.jchromb.2018.05.014
64
ZhangF.ZhangY.LiX.ZhangS.ZhuM.DuW.et al. (2018). Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association. Phytomedicine44, 220ā230. doi: 10.1016/j.phymed.2018.03.003
65
ZhangJ.WeiC.WangH.TangS.JiaZ.WangL.et al. (2013). Protective effect of Qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats. Evid. Based Complement Altern. Med.2013, 378298. doi: 10.1155/2013/378298
66
ZhangJ. H.ZhuY.FanX. H.ZhangB. L. (2015). Efficacy-oriented compatibility for component-based Chinese medicine. Acta Pharmacol. Sin.36, 654ā658. doi: 10.1038/aps.2015.8
67
ZhangR.ZhuX.BaiH.NingK. (2019). Network pharmacology databases for traditional Chinese medicine: review and assessment. Front. Pharmacol.10, 123. doi: 10.3389/fphar.2019.00123
68
ZhangY.ZhangL.FanX.YangW.YuB.KouJ.et al. (2019). Captopril attenuates TAC-induced heart failure via inhibiting wnt3a/beta-catenin and Jak2/Stat3 pathways. Biomed. Pharmacother.113, 108780. doi: 10.1016/j.biopha.2019.108780
69
ZhangZ.WeiC.ZhouY.YanT.WangZ.LiW.et al. (2017). Homocysteine induces apoptosis of human umbilical vein endothelial cells via mitochondrial dysfunction and endoplasmic reticulum stress. Oxid. Med. Cell. Longev.2017, 5736506. doi: 10.1155/2017/5736506
70
ZhouX.LiC.G.ChangD.BensoussanA. (2019). Current status and major challenges to the safety and efficacy presented by Chinese herbal medicine. Medicines (Basel)6, 14. doi: 10.3390/medicines6010014
Summary
Keywords
pharmacokinetics, network pharmacology, Qiliqiangxin capsule, chronic heart failure, HCMEC
Citation
Zhang Y, Zhu M, Zhang F, Zhang S, Du W and Xiao X (2019) Integrating Pharmacokinetics Study, Network Analysis, and Experimental Validation to Uncover the Mechanism of Qiliqiangxin Capsule Against Chronic Heart Failure. Front. Pharmacol. 10:1046. doi: 10.3389/fphar.2019.01046
Received
23 May 2019
Accepted
19 August 2019
Published
18 September 2019
Volume
10 - 2019
Edited by
Jincai Luo, Peking University, China
Reviewed by
Rongli Zhang, Case Western Reserve University, United States; Ren Jun Guo, Xiyuan Hospital,China
Updates
Copyright
Ā© 2019 Zhang, Zhu, Zhang, Zhang, Du and Xiao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wuxun Du, cnduwux@163.com; Xuefeng Xiao, kai1219@163.com
ā These authors have contributed equally to this work
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.